Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study
Hypofractionated intensity-modulated radiotherapy in locally advanced unresectable pancreatic cancer: A pilot study
复制标题
DOI：
10.1016/j.currproblcancer.2019.04.003
复制
发表时间：
2019-10-01
影响因子：
2.6
通讯作者：
Tombolini, Vincenzo
中科院分区：
文献类型：
--
作者：
De Felice, Francesca;Benevento, Ilaria;Tombolini, Vincenzo
目的：探讨大分割调强放疗（H-IMRT）治疗胰腺癌（PAC.Methods）的可行性和安全性。患者接受H-IMRT至肿瘤体积，总剂量为52戈伊（4戈伊/次）。毒性率，十二指肠剂量学参数，和临床outcomes.Results：10例患者接受H-IMRT方案。除1例患者外，所有患者均记录了客观肿瘤缓解。胃肠道毒性是最常见的急性副作用，其严重程度与十二指肠最大剂量（rho = 0.46）和暴露于5戈伊的十二指肠体积百分比（rho =0.46）中度相关。1年总生存率和无病生存率分别为83.3%和68.6%。其在不可切除的非转移性PAC中的应用需要进一步研究。(C)2019爱思唯尔公司All rights reserved.
Purpose: To test feasibility and safety of hypofractionated intensity modulated radiotherapy (H-IMRT) in pancreatic adenocarcinoma (PAC) treatment.Methods: Patients with unresectable nonmetastatic PAC were prospectively enrolled on a pilot study. Patients received H-IMRT to gross tumor volume to a total dose of 52 Gy (4 Gy/fraction). Toxicity rates, duodenal dosimetric parameters, and clinical outcomes were evaluated.Results: Ten patients received H-IMRT regimen. Objective tumor response was recorded in all patients but one. Gastrointestinal toxicity was the most common acute side effect and its severity moderately correlated with duodenal maximum dose (rho = 0.46) and percentage of duodenal volume exposed to 5 Gy (rho =0.46). The 1-year overall and disease-free survival were 83.3% and 68.6%, respectively.Conclusion: H-IMRT seems to guarantee a high local control rate without severe toxicity. Its use in unresectable non metastatic PAC needs to be further investigated. (C) 2019 Elsevier Inc. All rights reserved.